Wang Kui, Tang Yun, Tao Xiubin, Jiang Mengke, Dou Yunyou, Zhang Wei, Yu Tao, Wang Guiliang, Fan Zhen, Wu Nianlong
Department of Neurosurgery Intensive Care Unit, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui, China.
Department of Nursing, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College, Wuhu 241000, Anhui, China. Corresponding author: Tang Yun, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Feb;35(2):182-188. doi: 10.3760/cma.j.cn121430-20220822-00771.
To explore the prognostic effect and safety of neurally adjusted ventilatory assist (NAVA) mode on the patients with severe neurological cerebrovascular disease undergoing mechanical ventilation.
A prospective study was conducted. Fifty-four patients with cerebrovascular disease undergoing mechanical ventilation admitted to the neurosurgery intensive care unit (NSICU) of the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital) from December 2020 to May 2022 were enrolled. They were divided into NAVA group and pressure support ventilation (PSV) group by computer random number generator with 27 patients in each group. The ventilation time of the two groups was ≥ 72 hours. The general basic data of the two groups were recorded. The time without mechanical ventilation 28 days after enrollment, total length of mechanical ventilation, survival rate of 90 days after enrollment, length of NSICU stay, total length of hospital stay, NSICU mortality, in-hospital mortality, Glasgow outcome score (GOS), complications related to mechanical ventilation, and changes of respiratory mechanics indexes, arterial blood gases, vital signs, and diaphragm function indexes were observed.
The time without mechanical ventilation 28 days after enrollment in the NAVA group was significantly longer than that in the PSV group [days: 22 (15, 26) vs. 6 (0, 23), P < 0.05]. However, there were no significant differences in the total length of mechanical ventilation, 90-day survival rate, length of NSICU stay, total length of hospital stay, NSICU mortality, in-hospital mortality, GOS score, and incidence of mechanical ventilator-related complications between the two groups. In terms of respiratory mechanics parameters, the expiratory tidal volume (VTe) on 3 days after mechanical ventilation of patients in the NAVA group was significantly lower than that on 1 day and 2 days, and significantly lower than that in the PSV group [mL: 411.0 (385.2, 492.6) vs. 489.0 (451.8, 529.4), P < 0.01]. Minute ventilation (MV) at 2 days and 3 days in the NAVA group was significantly higher than that at 1 day, and significantly higher than that in the PSV group at 2 days [L/min: 9.8 (8.4, 10.9) vs. 7.8 (6.5, 9.8), P < 0.01], while there was no significant change of MV in the PSV group. At 1 day, peak airway pressure (Ppeak) and mean airway pressure (Pmean) in the NAVA group were significantly lower than those in the PSV group [Ppeak (cmHO, 1 cmHO ≈ 0.098 kPa): 14.0 (12.2, 17.0) vs. 16.6 (15.0, 17.4), Pmean (cmHO): 7.0 (6.2, 7.9) vs. 8.0 (7.0, 8.2), both P < 0.05]. However, there was no significant difference in the Ppeak or Pmean at 2 days and 3 days between the two groups. In terms of arterial blood gas, there was no significant difference in pH value between the two groups, but with the extension of mechanical ventilation time, the pH value at 3 days of the two groups was significantly higher than that at 1 day. Arterial partial pressure of oxygen (PaO) at 1 day in the NAVA group was significantly lower than that in the PSV group [mmHg (1 mmHg ≈ 0.133 kPa): 122.01±37.77 vs. 144.10±40.39, P < 0.05], but there was no significant difference in PaO at 2 days and 3 days between the two groups. There was no significant difference in arterial partial pressure of carbon dioxide (PaCO) or oxygenation index (PaO/FiO) between the two groups. In terms of vital signs, the respiratory rate (RR) at 1, 2, and 3 days of the NAVA group was significantly higher than that of the PSV group [times/min: 19.2 (16.0, 25.2) vs. 15.0 (14.4, 17.0) at 1 day, 21.4 (16.4, 26.0) vs. 15.8 (14.0, 18.6) at 2 days, 20.6 (17.0, 23.0) vs. 16.7 (15.0, 19.0) at 3 days, all P < 0.01]. In terms of diaphragm function, end-inspiratory diaphragm thickness (DTei) at 3 days in the NAVA group was significantly higher than that in the PSV group [cm: 0.26 (0.22, 0.29) vs. 0.22 (0.19, 0.26), P < 0.05]. There was no significant difference in end-expiratory diaphragm thickness (DTee) between the two groups. The diaphragm thickening fraction (DTF) at 2 days and 3 days in the NAVA group was significantly higher than that in the PSV group [(35.18±12.09)% vs. (26.88±8.33)% at 2 days, (35.54±13.40)% vs. (24.39±9.16)% at 3 days, both P < 0.05].
NAVA mode can be applied in patients with neuro-severe cerebrovascular disease, which can prolong the time without mechanical ventilation support and make patients obtain better lung protective ventilation. At the same time, it has certain advantages in avoiding ventilator-associated diaphragm dysfunction and improving diaphragm function.
探讨神经调节通气辅助(NAVA)模式对重症神经脑血管疾病机械通气患者的预后影响及安全性。
进行一项前瞻性研究。选取2020年12月至2022年5月在皖南医学院第一附属医院(弋矶山医院)神经外科重症监护病房(NSICU)住院的54例接受机械通气的脑血管疾病患者。通过计算机随机数字生成器将其分为NAVA组和压力支持通气(PSV)组,每组27例。两组通气时间均≥72小时。记录两组的一般基础数据。观察入组后28天无机械通气时间、机械通气总时长、入组后90天生存率、NSICU住院时长、总住院时长、NSICU死亡率、院内死亡率、格拉斯哥预后评分(GOS)、机械通气相关并发症、呼吸力学指标、动脉血气、生命体征及膈肌功能指标的变化。
NAVA组入组后28天无机械通气时间显著长于PSV组[天数:22(15,26) vs. 6(0,23),P<0.05]。然而,两组在机械通气总时长、90天生存率、NSICU住院时长、总住院时长、NSICU死亡率、院内死亡率、GOS评分及机械通气相关并发症发生率方面无显著差异。在呼吸力学参数方面,NAVA组患者机械通气3天时的呼气潮气量(VTe)显著低于1天和2天时,且显著低于PSV组[毫升:411.0(385.2,492.6) vs. 489.0(451.8,529.4),P<0.01]。NAVA组2天和3天时的分钟通气量(MV)显著高于1天时,且2天时显著高于PSV组[升/分钟:9.8(8.4,10.9) vs. 7.8(6.5,9.8),P<0.01],而PSV组MV无显著变化。1天时,NAVA组的气道峰压(Ppeak)和平均气道压(Pmean)显著低于PSV组[Ppeak(厘米水柱,1厘米水柱≈0.098千帕):14.0(12.2,17.0) vs. 16.6(15.0,17.4),Pmean(厘米水柱):7.0(6.2,7.9) vs. 8.0(7.0,8.2),均P<0.05]。然而,两组在2天和3天时的Ppeak或Pmean无显著差异。在动脉血气方面,两组pH值无显著差异,但随着机械通气时间延长,两组3天时的pH值显著高于1天时。NAVA组1天时的动脉血氧分压(PaO)显著低于PSV组[毫米汞柱(1毫米汞柱≈0.133千帕):122.01±37.77 vs. 144.10±40.39,P<0.05],但两组在2天和3天时的PaO无显著差异。两组的动脉血二氧化碳分压(PaCO)或氧合指数(PaO/FiO)无显著差异。在生命体征方面,NAVA组1、2和3天时的呼吸频率(RR)显著高于PSV组[次/分钟:1天时19.2(16.0,25.2) vs. 15.0(14.4,17.0),2天时21.4(16.4,26.0) vs. 15.8(14.0,18.6),3天时20.6(17.0,23.0) vs. 16.7(15.0,19.0),均P<0.01]。在膈肌功能方面,NAVA组3天时的吸气末膈肌厚度(DTei)显著高于PSV组[厘米:0.26(0.22,0.29) vs. 0.22(0.19,0.26),P<0.05]。两组呼气末膈肌厚度(DTee)无显著差异。NAVA组2天和3天时的膈肌增厚分数(DTF)显著高于PSV组[2天时(35.18±12.09)% vs. (26.88±8.33)%,3天时(35.54±13.40)% vs. (24.39±9.16)%,均P<0.05]。
NAVA模式可应用于神经重症脑血管疾病患者,可延长无机械通气支持时间,使患者获得更好的肺保护性通气。同时,在避免呼吸机相关性膈肌功能障碍和改善膈肌功能方面具有一定优势。